AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY26 results · Jul–Sep 2025
AstraZeneca Pharma India reported revenue from operations of ₹559.09 crore (up 37.0% from Q2 FY25) and net profit of ₹54.22 crore (up 41.1% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 559.09 | 408.00 | +37.0% | 526.31 | +6.2% |
| Other income | 6.17 | 8.15 | −24.3% | 11.24 | −45.1% |
| Total income | 565.26 | 416.15 | +35.8% | 537.55 | +5.2% |
| Profit before tax | 72.82 | 51.03 | +42.7% | 74.70 | −2.5% |
| Net profit for the period | 54.22 | 38.43 | +41.1% | 55.83 | −2.9% |
| EPS, basic (₹) | 21.69 | 15.37 | +41.1% | 22.33 | −2.9% |
| Net margin (%) | 9.7 | 9.4 | 10.6 |
Standalone
- Filed with BSE
- 07 Nov 2025, 18:11 IST
- Board meeting
- 07 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE